| 货号 | 16239-50mg |
| 描述 | ATP citrate lyase (ACL) catalyzes the synthesis of acetyl-CoA and oxaloacetate using citrate, CoA, and ATP as substrates and Mg2+ as a cofactor.1 The ACL-dependent synthesis of acetyl-CoA is important for the de novo synthesis of fatty acids and cholesterol.2 Furthermore, as a key enzyme for linking glucose and lipid metabolism, ACL is thought to contribute to the Warburg effect in cancer cells.3 BMS 303141 is a cell-permeable, 2-hydroxy-N-arylbenzenesulfonamide that inhibits ACL with an IC50 value of 0.13 µM.4 At an oral dose of 100 mg/kg/day, BMS 303141 has been reported to reduce weight gain and lower plasma cholesterol, triglycerides, and glucose in a mouse model of hyperlipidemia.4 |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Ma, Z.,Chu, C.H. and Cheng, D. A novel direct homogeneous assay for ATP citrate lyase. Journal of Lipid Research 50(10), 2131-2135 (2009). 2.Dufort, F.J.,Gumina, M.R.,Ta, N.L., et al. Glucose-dependent de novo lipogenesis in B lymphocytes: A requirement for ATP-citrate lyase in lipopolysaccharide-induced differentiation. The Journal of Biological Chemisty 289(10), 7011-7024 (2014). 3.Zu, X.Y.,Zhang, Q.H.,Liu, J.H., et al. ATP citrate lyase inhibitors as novel cancer therapeutic agents. Recent Pat.Anticancer Drug Discov. 7(2), 154-167 (2012). 4.Li, J.J.,Wang, H.,Tino, J.A., et al. 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorganic & Medicinal Chemistry Letters 17(11), 3208-3211 (2007). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 424.3 |
| 分子式 | C19H15Cl2NO4S |
| CAS号 | 943962-47-8 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |